Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

VV913 clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 2 trials in our China register that name VV913 as an intervention. Synced 10 Nov 2026
2Current trials
1Recruiting now
1Lead sponsor
1Country register
At a glance

VV913 is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 1. The lead sponsor is Vigonvita Life Sciences. The most-studied condition is Healthy Volunteers.

Patient leaflets for VV913

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting150%
  • Not yet open150%

Trials by phase

  • Phase 1150%
  • Phase 2150%
01

Clinical trials of VV913

2 trials
StudyPhaseStatusLead sponsorRegisters
Study of Food Effects of VV913 Capsules in Chinese Healthy Volunteers
NCT07565792 · ClinicalTrials.gov ↗ · Healthy Volunteers
Phase 1 Recruiting Vigonvita Life Sciences China
Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of PE
NCT07722780 · ClinicalTrials.gov ↗ · Premature Ejaculation
Phase 2 Not yet open Vigonvita Life Sciences China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with VV913

2 conditions
Healthy Volunteers1Premature Ejaculation1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Vigonvita Life Sciences2
04

By country register

RegisterTrialsRecruiting
Clinical trials in China21

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about VV913 trials

How many clinical trials are testing VV913?

2 current trials in our China register name VV913 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are VV913 trials recruiting patients?

Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors VV913 clinical trials?

The lead sponsor is Vigonvita Life Sciences. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how VV913 works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how VV913 works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists VV913 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.